According to a recent LinkedIn post from Xeltis, members of its senior clinical leadership are scheduled to attend the American Society of Diagnostic and Interventional Nephrology 22nd Annual Scientific Meeting in Florida in February 2026. The post notes that the Vice President of US Clinical Affairs and the Vice President of Clinical Business Development will be present at the event.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that Dr. Adrian Sequira, a professor of clinical medicine and director of interventional nephrology at Louisiana State Health Sciences Center, is expected to present updates on the clinical progress of aXess, described as Xeltis’ restorative vascular access conduit. The session, titled “The Living Conduit,” is scheduled for Saturday, February 21, 2026, from 1:45 PM to 2:45 PM EST.
The post suggests that Xeltis is positioning aXess within the dialysis and vascular access segment, emphasizing ongoing clinical trials and advancement toward potential commercialization. For investors, visible engagement at a specialized nephrology meeting and third-party clinical presentations may signal progress in validating the technology and building awareness among key clinical stakeholders.
As referenced in the LinkedIn content, the call to connect with the Xeltis team at the conference indicates a focus on relationship-building with clinicians and possibly strategic partners or trial sites. If clinical data for aXess prove favorable, the company’s activity in this forum could support future adoption prospects, which may be relevant for assessing long-term revenue potential in the vascular access market.